3061406-99-0
Chemical Structure
Vortosiran
Synonym(s): RBD4059
- CAS No.: 3061406-99-0
- Formula:C463H620F7N154O291P39S6
- Molecular Weight:14532.10
SMILES: [Vortosiran]
Biological Activity: Vortosiran (RBD4059) is a siRNA that inhibits the synthesis of coagulation factor XI (FXI). Vortosiran shows potent inhibitory activity against mouse FXI transcripts with an IC50 of 69 pM; it exerts similar effects on common FXI transcripts from humans and monkeys, with an IC50 of 59 pM. Vortosiran is internalized via ASGPR-mediated endocytosis, subsequently regulating mRNA translation to suppress FXI synthesis. Vortosiran exhibits antithrombotic activity without impairing hemostatic function. Vortosiran can be used in research related to intravascular thrombosis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vortosiran | 97.76% | Vortosiran (RBD4059) is a siRNA that inhibits the synthesis of coagulation factor XI (FXI). Vortosiran shows potent inhibitory activity against mouse FXI transcripts with an IC50 of 69 pM; it exerts similar effects on common FXI transcripts from humans and monkeys, with an IC50 of 59 pM. Vortosiran is internalized via ASGPR-mediated endocytosis, subsequently regulating mRNA translation to suppress FXI synthesis. Vortosiran exhibits antithrombotic activity without impairing hemostatic function. Vortosiran can be used in research related to intravascular thrombosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Gabrielsen A, et al. RNA interference therapy targeting coagulation factor XI: a first-in-human trial of RBD4059 (vortosiran). Blood advances. 2026 Apr 14;10(7):2541-2548. [Content Brief]
-
[2]. Liang, J., et al. (2025). Inhibition of Factor XI using RBD4059: a novel GalNAc-siRNA with potent and durable antithrombotic effects. Basic to Translational Science, 10(6), 786-797.
- [3]. Yuan H, et al. Beyond traditional anticoagulants: exploring the future of thromboembolism treatment with FXI inhibitors. Front Immunol. 2026 Oct 5;17:1925585. [Content Brief]
